Cite
HARVARD Citation
Guan, Y. et al. (2018). A long‐acting pegylated recombinant human growth hormone (Jintrolong®) in healthy adult subjects: Two single‐dose trials evaluating safety, tolerability and pharmacokinetics. Journal of clinical pharmacy and therapeutics. pp. 640-646. [Online].